<code id='908C93D5A4'></code><style id='908C93D5A4'></style>
    • <acronym id='908C93D5A4'></acronym>
      <center id='908C93D5A4'><center id='908C93D5A4'><tfoot id='908C93D5A4'></tfoot></center><abbr id='908C93D5A4'><dir id='908C93D5A4'><tfoot id='908C93D5A4'></tfoot><noframes id='908C93D5A4'>

    • <optgroup id='908C93D5A4'><strike id='908C93D5A4'><sup id='908C93D5A4'></sup></strike><code id='908C93D5A4'></code></optgroup>
        1. <b id='908C93D5A4'><label id='908C93D5A4'><select id='908C93D5A4'><dt id='908C93D5A4'><span id='908C93D5A4'></span></dt></select></label></b><u id='908C93D5A4'></u>
          <i id='908C93D5A4'><strike id='908C93D5A4'><tt id='908C93D5A4'><pre id='908C93D5A4'></pre></tt></strike></i>

          Home / comprehensive / explore

          explore


          explore

          author:knowledge    Page View:6595
          Franklin faces
          Adobe

          ARCH Venture Partners, one of the top investors in the biotech ecosystem, is raising $3 billion for a new fund.

          The Chicago-based firm filed paperwork with the Securities and Exchange Commission this week for what would be its 13th namesake fund. Arch estimated it would raise around $3 billion — roughly the same amount it raised during its more recent fundraising in 2022.

          advertisement

          Arch declined to comment on the new fundraising.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In